Timolol metabolism in human liver microsomes is mediated principally by CYP2D6

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1135-1141

  Volotinen, Marjo ^a   Turpeinen, Miia ^b   Tolonen, Ari ^c,d   Uusitalo, Jouko ^d   Mäenpää, Jukka ^a   Pelkonen, Olavi ^b  

^a Santen Oy   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Department of Chemistry ^*  (Finland)

^d Novamass Analytical Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; ENZYME INHIBITOR; FLUVOXAMINE; QUINIDINE; TIMOLOL;

ANIMAL CELL; ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME METABOLISM; HALF LIFE TIME; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; METABOLITE; METHYLATION; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DEALKYLATION; DEXTROMETHORPHAN; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; QUINIDINE; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIMOLOL;

EID: 34250713864     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012906     Document Type: Article

References (28)

1. Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, and Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966-972.
2. Blumenfeld A (2005) Clinical approaches to migraine prophylaxis. Am J Manag Care 11 (2 Suppl):S55-S61.
3. Brooks AM and Gillies WE (1992) Ocular β-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 2:208-221.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (N Y) 10:1093-1095.
5. Dollery C, Boobis AR, Burley D, Davies DS, Harrison PI, Orme ML, Park BK, and Goldberg LI (1991) Timolol (maleate), in Therapeutic Drugs, vol 2 (Dollery C, ed) pp T77-T80. Churchill Livingstone, London.
6. Dunn FG and Frohlich ED (1981) Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent. Pharmacotherapy 1:188-200.
7. Edeki TI, He H, and Wood AJ (1995) Pharmacogenetic explanation for excessive β-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 274:1611-1613.
8. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
9. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
10. Ishii Y, Nakamura K, Tsutsumi K, Kategawa T, Nakano S, and Nakatsuka K (2000) Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol 40:193-199.
11. Kaila T, Huupponen R, Karhuvaara S, Havula P, Scheinin M, Iisalo E, and Salminen L (1991) Beta-blocking effects of timolol at low plasma concentrations. Clin Pharmacol Ther 49:53-58.
12. Korte JM, Kaila T, and Saari KM (2002) Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eye drops. Graefes Arch Clin Exp Ophthalmol 240:430-435.
13. Lennard MS, Tucker GT, and Woods HF (1986) The polymorphic oxidation of beta adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet 11:1-17.
14. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, and Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399-407.
15. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, and Kuritsky JN (1986) Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 102:606-611.
16. Nieminen T, Uusitalo H, Mäenpää J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimäki T, and Kähönen M (2005a) Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. Eur J Clin Pharmacol 61:811-819.
17. Nieminen T, Uusitalo H, Turjanmaa V, Bjärnhall G, Hedenström H, Mäenpää J, Ropo A, Heikkilä P, and Kähönen M (2005b) Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 61:369-374.
18. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, and Raunio H (1998) Inhibition and induction of human P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
19. Rowland-Yeo K, Rostami-Hodjegan A, and Tucker GT (2004) Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687-688.
20. Shell JW (1982) Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 26:207-218.
21. Taavitsainen P, Juvonen R, and Pelkonen O (2001) In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29:217-222.
22. Tocco DJ, Duncan AE, DeLauna FA, Hucker HB, Gruber VF, and Vandenheuvel WJA (1975) Physiological disposition and metabolism of timolol in man and laboratory animals. Drug Metab Dispos 3:361-370.
23. Tocco DJ, Duncan AE, DeLuna FA, Smith JL, Walker RW, and Vandenheuvel WJA (1980) Timolol metabolism in man and laboratory animals. Drug Metab Dispos 8:236-240.
24. Tolonen A, Turpeinen M, Uusitalo J, and Pelkonen O (2005) A simple method for differentiation of monoisotopic drug metabolites with hydrogen-deuterium exchange liquid chromatography/electrospray mass spectrometry. Eur J Pharm Sci 25:155-162.
25. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, and Pelkonen O (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631.
26. Uusitalo H, Niño J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J, and Kähönen M (2005) Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand 83:723-728.
27. Van Buskirk EM (1980) Adverse reactions from timolol administration. Ophthalmology 87:447-450.
28. Zanger UM, Raimundo S, and Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37.